By 2016, ADA guidelines cited cardiovascular benefit from SGLT‐2 inhibitors and reduction in cardiovascular risk factors from GLP‐1 receptor agonists as advantages, and by 2021 explicitly favoured these drug classes for large subgroups of patients with diabetes.22 Here, GLP1R is linked to diabetes mellitus.